drugset / Trial / NCT02416622
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
Timeline
- Start
- 2015-05
- Primary completion
- 2019-04
- Completion
- 2023-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rAAV2tYF-CB-hRS1 | Gene therapy (AAV / viral vector) | — | Intravitreal |